This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Drug Therapy  • Alert me on articles by topic

A Case-Control Study

Vijayvel Jayaprakash, MBBS; Nestor R. Rigual, MD; Kirsten B. Moysich, PhD; Thom R. Loree, MD; Maureen A. Sullivan Nasca, DDS; Ravi J. Menezes, MSc; Mary E. Reid, PhD

Arch Otolaryngol Head Neck Surg. 2006;132:1231-1236.

Objective  To evaluate the chemopreventive potential of aspirin against head and neck cancer.

Design  Hospital-based case-control study.

Setting  National Cancer Institute–designated comprehensive cancer center.

Patients  Individuals who received medical services at the Roswell Park Cancer Institute, Buffalo, NY, between 1982 and 1998 and who completed a comprehensive epidemiologic questionnaire.

Main Outcome Measure  Aspirin use among 529 patients with head and neck cancer and 529 hospital-based control subjects matched by age, sex, and smoking status.

Results  Aspirin use was associated with a 25% reduction in the risk of head and neck cancer (adjusted odds ratio, 0.75; 95% confidence interval, 0.58-0.96). Consistent risk reductions were also noted in association with frequent and prolonged aspirin use. Further, a consistently decreasing trend in risk was noted with increasing duration of aspirin use (P_trend = .005). Risk reduction was observed across all 5 primary tumor sites, with cancers of the oral cavity and oropharynx exhibiting greater risk reduction. When analyzed by smoking and alcohol exposure levels, participants moderately exposed to either showed a statistically significant 33% risk reduction (adjusted odds ratio, 0.67; 95% confidence interval, 0.50-0.91), whereas participants exposed to both heavy smoking and alcohol use did not benefit from the protective effect of aspirin. The reduction in risk was relatively more significant in women.

Conclusions  Aspirin use is associated with reduced risk of head and neck cancer. This effect is more pronounced in individuals with low to moderate exposure to cigarette smoke or alcohol consumption.

Author Affiliations: Departments of Epidemiology, Division of Cancer Prevention and Population Sciences (Drs Jayaprakash, Moysich, and Reid and Mr Menezes), Head and Neck/Plastic Surgery (Drs Rigual and Loree), and Dentistry and Maxillofacial Prosthetics (Dr Sullivan Nasca), Roswell Park Cancer Institute, Buffalo, NY.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chemoprevention of Head and Neck Cancers: Promising New Biochemical Prospects
Kapoor
JCO 2008;26:2417-2418.
FULL TEXT